Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
GSTP1 2950 GLUTATHIONE CHEMBL1543 DrugBank 17465221, 17517071
GSTP1 2950 CARBOCYSTEINE CHEMBL396416 DrugBank 17139284, 17016423, 10592235
GSTP1 2950 DROLOXIFENE CHEMBL487 NCI 11721384
GSTP1 2950 ETHACRYNIC ACID CHEMBL456 NCI 10900222
GSTP1 2950 ALCOHOL CHEMBL545 NCI 1302037
GSTP1 2950 OXALIPLATIN CHEMBL414804 NCI 12072547
GSTP1 2950 RESVERATROL CHEMBL165 NCI 11279601
GSTP1 2950 MERCAPTOPURINE CHEMBL1425 PharmGKB
GSTP1 2950 DOCETAXEL CHEMBL92 NCI 10639573
GSTP1 2950 CYTARABINE CHEMBL803 NCI 3978635
GSTP1 2950 CHEMBL345292 CHEMBL345292 DrugBank 17139284, 17016423, 10592235
GSTP1 2950 CARBOPLATIN CHEMBL1351 NCI, CIViC 12360105, 25010864
GSTP1 2950 DEXAMETHASONE CHEMBL384467 NCI 1302037
GSTP1 2950 EXATECAN MESYLATE CHEMBL2106563 NCI 10639573
GSTP1 2950 THIOTEPA CHEMBL671 PharmGKB
GSTP1 2950 GLYCERIN CHEMBL692 DrugBank 17139284, 17016423
GSTP1 2950 EZATIOSTAT HYDROCHLORIDE CHEMBL2103810 inhibitor ChemblInteractions, DrugBank 10592235
GSTP1 2950 DECITABINE CHEMBL1201129 NCI 11948118, 11960994
GSTP1 2950 CURCUMIN CHEMBL116438 NCI 15999103
GSTP1 2950 GARLIC CHEMBL2108463 NCI 11962257
GSTP1 2950 IFOSFAMIDE CHEMBL1024 NCI 16282887
GSTP1 2950 LYCOPENE CHEMBL501174 NCI 10806309
GSTP1 2950 MECHLORETHAMINE HYDROCHLORIDE CHEMBL1201001 NCI 2882834
GSTP1 2950 OMEPRAZOLE CHEMBL1503 NCI 8529327
GSTP1 2950 EPIRUBICIN CHEMBL417 PharmGKB
GSTP1 2950 EZATIOSTAT CHEMBL2110585 TdgClinicalTrial
GSTP1 2950 PACLITAXEL CHEMBL428647 CIViC 25010864
GSTP1 2950 CIBACRON BLUE CHEMBL572528 DrugBank 17139284, 17016423
GSTP1 2950 CAMPTOTHECIN CHEMBL65 NCI 15500952
GSTP1 2950 IRINOTECAN CHEMBL481 NCI 10639573
GSTP1 2950 MIFEPRISTONE CHEMBL1276308 NCI 1302037
GSTP1 2950 PYRIMETHAMINE CHEMBL36 PharmGKB
GSTP1 2950 ETOPOSIDE CHEMBL44657 PharmGKB
GSTP1 2950 PERFOSFAMIDE CHEMBL61511 NCI 9382956
GSTP1 2950 AZACITIDINE CHEMBL1489 NCI 11696442
GSTP1 2950 CYCLOPHOSPHAMIDE CHEMBL88 NCI 9382956
GSTP1 2950 MELPHALAN CHEMBL852 NCI 15779864, 1988111
GSTP1 2950 MISONIDAZOLE CHEMBL42161 NCI 3753520
GSTP1 2950 SELENOMETHIONINE CHEMBL113178 NCI 1759407
GSTP1 2950 DITIOCARB CHEMBL961 NCI 2992773
GSTP1 2950 HYDROQUINONE CHEMBL537 NCI 15141365
GSTP1 2950 PREDNISONE CHEMBL635 NCI 11186134, 10050715
GSTP1 2950 SULFORAPHANE CHEMBL48802 NCI 1549603
GSTP1 2950 VITAMIN E CHEMBL47 NCI 17029404
GSTP1 2950 PRIDINOL CHEMBL404215 NCI 16127053
GSTP1 2950 BUSULFAN CHEMBL820 NCI 15779864
GSTP1 2950 VERAPAMIL CHEMBL6966 NCI 3566185
GSTP1 2950 CANFOSFAMIDE CHEMBL2111086 TdgClinicalTrial, DrugBank 16014111, 12738715
GSTP1 2950 SODIUM BUTYRATE CHEMBL62381 NCI 12896903
GSTP1 2950 DAUNORUBICIN CHEMBL178 NCI 10050715

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
GSTP1 rs1138272 C oxaliplatin "toxicity","metabolism/PK" no Allele C is not associated with response to oxaliplatin in people with Gastrointestinal Neoplasms as compared to allele T. 16707601 637880191
GSTP1 rs1695 AA + AG cyclophosphamide efficacy yes Genotypes AA + AG are associated with increased response to cyclophosphamide and epirubicin in women with Breast Neoplasms as compared to genotype GG. 21362365 827704840
GSTP1 rs1695 A cyclophosphamide efficacy yes Significant when combined with the GSTT1 non-null genotype. Allele A is associated with increased response to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G. 20568049 827704813
GSTP1 rs1695 AG + GG fluorouracil efficacy yes Increased likelihood of a better response rate in those with AG or GG genotype compared to AA. Genotypes AG + GG are associated with increased response to fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to genotype AA. 21449681 827793307
GSTP1 rs1695 AA Platinum compounds efficacy no This association was only significant in the Asian population. When studied together with the Caucasian population significance was lost. Genotype AA is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG. 22761669 982046503
GSTP1 rs1695 G gemcitabine metabolism/PK no Allele G is not associated with clearance of gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele A. 21590444 1446900797
GSTP1 rs1695 AA olanzapine metabolism/PK yes A = *A and G = *B. This result was ONLY significant in univariate analysis, and NOT significant in multiple regression analysis. Genotype AA is associated with increased clearance of olanzapine in healthy individuals as compared to genotypes AG + GG. 23559402 1183703811
GSTP1 rs1695 A anthracyclines and related substances efficacy yes Allele A is associated with increased response to anthracyclines and related substances in women with Breast Neoplasms as compared to allele G. 27785604 1448635319
GSTP1 rs1695 GG imatinib efficacy no Genotype GG is not associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG. 25188725 1444672955
GSTP1 rs1695 G fluorouracil efficacy no Allele G is not associated with response to fluorouracil, leucovorin and oxaliplatin in people with Esophageal Neoplasms and Stomach Neoplasms as compared to allele A. 25232828 1184886901
GSTP1 rs1695 G epirubicin efficacy not stated Allele G is not associated with response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms. 25545243 1444694879
GSTP1 rs1695 AA cyclophosphamide "efficacy","toxicity","metabolism/PK" no Genotype AA is not associated with increased response to cyclophosphamide in people with Lupus Nephritis as compared to genotypes AG + GG. 26222310 1447676185
GSTP1 rs1695 G cyclophosphamide metabolism/PK no Allele G is not associated with metabolism of cyclophosphamide in people with as compared to allele A. 26456622 1446907901
GSTP1 rs1695 GG dimethyl fumarate efficacy yes Genotype GG is associated with decreased response to dimethyl fumarate in people with Psoriasis as compared to genotypes AA + AG. 26967570 1447963626
GSTP1 rs1695 AA + AG bevacizumab efficacy no No significant association with response, progression-free survival or overall survival was found for this variant. Please note that alleles have been complemented to the plus chromosomal strand. Genotypes AA + AG are not associated with response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotype GG. 27995989 1448568344
GSTP1 rs1695 AG + GG cyclophosphamide efficacy no This variant in GSTP1 was associated with treatment failure but was not significant after adjustment for multiple testing. Genotypes AG + GG is associated with decreased response to cyclophosphamide in people with Lupus Nephritis as compared to genotype AA. 28976264 1449004938
GSTP1 rs1695 G cyclophosphamide efficacy no Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A. 29938344 1449576756
GSTP1 rs1695 GG fluorouracil efficacy no Patients were taking either IFL (irinotecan + fluorouracil + leucovorin; n=114), FOLFOX (fluorouracil + oxaliplatin + leucovorin; n=299) or IROX (irinotecan + oxaliplatin; n=107). No significant association was seen between this variant and confirmed response rate in any of the treatment groups OR all treatment groups considered together. Significance level was set at 0.01. Please note that alleles have been complemented to the plus chromosomal strand. Genotype GG is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG. 20530282 1448522297